Skip to content

Multi-modality imaging for differential diagnosis of intractable solid pulmonary nodule

Multi-modality imaging for differential diagnosis of intractable solid pulmonary nodule

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036589
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid pulmonary nodule

Interventions

Index test:correlation&#32
and&#32
maging&#32
parameters(IVIM-DWI(D,&#32
D*?f)
DCE-MRI(TIC&#32
type?T1&#32
mapping?iAUC?Ktrans?Kep?Ve?TTP?MAX&#32
Conc?MAX&#32
Slope)?PET-CT(SUVmean?SUVmax?SUVmin?MTV?TLG))

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.pulmonary nodules which is difficult to diagnose on CT: without any significant characteristics of malignancy or benignancy on CT imaging, for example, fat, harsh calcification, lobulation, bubble-like lucency and pleural indentation; 2.8mm <= tumor diameter <= 30mm; 3.no claustrophobia; 4.without hypersensitive to contrast agent; 5.liver and kidney function can afford the application of contrast agent; 6.without severe cardiorespiratory insufficiency or organ dysfunction; 7.patients can complete all of the imaging examinations; 8.without contraindication of MRI scanning; 9.patients undergo surgery or follow-up CT finds the tumor vanish, diminish, or stable for at least two years; 10.volunteer and sign an informed consent.

Exclusion criteria

Exclusion criteria: 1. Typical characteristics be found on CT imaging; 2. tumor diameter <= 8mm, which might not be found on MRI sequences; 3. the location of the nodule which is liable to cause motion artifact: close to heart or aorta; 4. any serious abnormalities such as cardiovascular diseases, organ or system dysfunction; 5. abnormality of CBC, liver and Kidney Function; 6. pregnant woman or to be pregnant female patient; 7. active B or C type hepatitis; 8. carriers of HIV; 9. any other current malignancy or malignancy history; 10. contraindication of MRI scanning.

Design outcomes

Primary

MeasureTime frame
benignancy/malignancy;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactYe Xiaodan

Shanghai Chest Hospital

yuanyxd@163.com+86 13761459998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026